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E-mail address: myim@sookmyung.ac.kr (M. Yim)We investigated the interplay between parathyroid hormone (PTH) and phosphodiesterases (PDEs)
in osteoblasts. PDE4 negatively regulated PTH-induced cAMP accumulation. PDE4 inhibitor
enhanced PTH-induced osteoclast formation and RANKL mRNA expression, which is partially med-
iated by COX-2 mRNA expression. Two CRE sites in the COX-2 promoter were required for the
increase in COX-2 transcription by PDE4 inhibitor, and the expression of a dominant-negative form
of CREB abolished COX-2 mRNA expression in response to PDE4 inhibitor or PTH in osteoblasts.
Taken together, our data indicate that PDE4 inhibitor promotes PTH-induced osteoclast formation
partially via CRE-mediated COX-2 mRNA expression.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction tic cells [7,8]. Notably, COX-2 expression is also required for theOsteoclasts are bone-resorbing, multinucleated cells that are
derived from the monocyte-macrophage lineage under the tight
regulation of stromal/osteoblastic cells [1–4]. In co-cultures of
mouse bone marrow cells and calvarial osteoblasts, osteoclasts
are formed in response to several osteotropic factors, including
1,25-dihydroxyvitamin D3 [1,25(OH)2D3], interleukin (IL)-6 plus
soluble IL-6 receptor, and prostaglandin E2 (PGE2) [2,3]. These fac-
tors induce the expression of receptor activator of NFjB ligand
(RANKL, also known as TRANCE, ODF, or OPGL) in osteoblasts
[4,5]. The binding of RANKL to its cognate receptor, RANK, which
is expressed on the surface of osteoclast progenitor cells, induces
osteoclastogenesis and activates osteoclasts, resulting in increased
bone resorption.
Parathyroid hormone (PTH) is one of the main hormones regu-
lating bone resorption. PTH stimulates osteoclast formation by
binding to its receptor, PTH receptor 1 (PTHR1), on stromal/osteo-
blastic cells, leading to the increased production of RANKL [6]. The
stimulation of RANKL by PTH requires cyclooxygenase-2 (COX-2)
expression via cyclic AMP (cAMP) production in stromal/osteoblas-chemical Societies. Published by E
.full induction of RANKL by IL-1, -6, and -17, basic ﬁbroblast growth
factor (bFGF), and 1,25(OH)2D3, indicating that COX-2 is a common
component in various osteoclastogenic signaling pathways [9].
It was recently suggested that the properties of cAMP-induced
signals are shaped by the presence of a large array of cyclic nucle-
otide phosphodiesterases (PDEs) [10]. PDEs are enzymes that de-
grade and inactivate cAMP/cGMP. The more than 20 genes
encoding PDEs in the mammalian genome can be subdivided into
11 families based on sequence homology, substrate speciﬁcity,
and inhibitor sensitivity. In addition, most PDE genes are expressed
as multiple variants through the use of different promoters or
alternative splicing, generating up to 100 individual PDE proteins,
which implies a complex array of functions for these enzymes.
PDEs involved in the degradation of cAMP include PDE1, 2, 3, 4,
7, 8, 10, and 11 [11].
Although PTH has been shown to stimulate osteoclast forma-
tion via a cAMP-dependent mechanism in osteoblasts, no data
are available regarding the pattern of interaction between PTH
and PDEs. Thus, in the present study, we used various PDE inhibi-
tors to identify the PDEs involved in PTH signaling in osteoblasts,
which in turn regulate osteoclast formation. Understanding the
mode of interaction between PTH and PDEs has important pharma-
cological and clinical implications for bone-related diseases.lsevier B.V. All rights reserved.
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2.1. Reagents
PTH (human, 1–34) was purchased from Anygen Co., Ltd.
(Gwang-ju, Korea). Antibodies against COX-2 and b-actin were pur-
chased from Cell Signaling Technology (Beverly, MA, USA). All
other reagents were from Sigma–Aldrich (St. Louis, MO).
2.2. Cells and culture system
Primary calvarial osteoblasts were obtained from the calvar-
iae of neonatal ICR mice (Samtako Inc., Korea) as described be-
fore [12]. The murine osteoblastic cell line MC3T3-E1 subclone
4 cells (MC-4) [13] was purchased from the American Type Cul-
ture Collection (Manassas, VA). Cells were maintained in a-MEM
containing 10% fetal bovine serum, 100 units/ml penicillin, and
100 lg/ml streptomycin. Bone marrow cells were obtained from
the long bones of 4- to 6-week-old ICR male mice. To examine
osteoclast formation, mouse bone marrow cells (1  105 cells)
were co-cultured with osteoblasts (5  103 cells) in the presence
or absence of PDE inhibitors and/or PTH (100 nM) in 96-well cul-
ture plates (CORNING, MA, USA). After 6 days of culture, cells
were ﬁxed and stained for tartrate-resistant acid phosphatase
(TRAP), a marker enzyme of osteoclasts, as described previously
[12].
2.3. cAMP measurement
Calvarial osteoblasts were treated with PTH (100 nM) in the
presence or absence of PDE inhibitors for the indicated hours.
Intracellular cAMP concentrations were measured using a com-
mercially available cAMP enzyme-immunoassay kit (Amersham
Biosciences, Bukinghamshire, UK) according to the manufacturer’s
protocol.
2.4. Northern blot analysis
Calvarial osteoblasts were cultured with agents for the indi-
cated periods and then subjected to total RNA extraction using Tri-
zol reagent (Invitrogen, CA, USA). Total RNA (20 lg) was
electrophoresed on 1.2% agarose-formaldehyde gels, transferred
to nylon membrane ﬁlters (Hybond N+, Amersham Biosciences,
Bukinghamshire, UK), and hybridized with 32P-labeled cDNA
probes. After the ﬁnal wash, the membranes were exposed to X-
ray ﬁlm (BioMax, Kodak, Rochester, NY) at 70 C.
2.5. Gene knock-down by oligonucleotide siRNA
The 22-nucleotide small interfering RNA (siRNA) for COX-2 and
negative control (scrambled) was purchased from Dharmacon
(Colorado, USA). For siRNA transfection, mouse osteoblastic MC-4
cells were seeded in 6-well plate at a density of 2  105 cells/well.
Twenty-four hours later, cells were transfected with 100 nM siRNA
using lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to
the manufacturer’s instructions. The transfection took place in
2 ml serum-free media for 6 h after which the cells were cultured
for 24 h in complete media. And then the cells were harvested for
immunoblot, RT-PCR or osteoclast formation analysis.
2.6. RT-PCR analysis
Total RNA was prepared using easy-BLUE (iNtRON Biotechnol-
ogy, Seoul, Korea) and cDNAs were synthesized from 1 lg of RNA
using RevertAid First Strand cDNA Synthesis Kit (Fermantas, Han-over, MD). The PCR primer sequences used are as follows: RANKL,
50-ccagccatttgcacacctc-30 (forward), 50-agcagggaagggttggaca-30 (re-
verse); b-actin, 50-tgtgatggtgggaatgggtcag-30 (forward), 50-tttgatgt-
cacgcacgatttcc-30 (reverse). The PCR program was as follows: 32
(RANKL) or 22 (b-actin) cycles, after an initial denaturation step
at 94 C for 3 min, then denaturation at 94 C for 30 s, annealing
at 58 C for 45 s, and extension at 72 C for 60 s, with a ﬁnal exten-
sion at 72 C for 10 min.
2.7. Immunoblot analysis
Total cell lysates were isolated, separated by SDS–PAGE, and
transferred onto Immobilon-P membranes (Millipore, Bedford,
MA, USA). The membranes were blocked with 5% non-fat-milk in
TBS-T, and then immunostained with anti-COX-2 (1:1000) or with
b-actin (1:4000) antibody followed by secondary horseradish per-
oxidase-conjugated antibody (1:5000). The membranes were
developed using an enhanced chemiluminescence detection kit
(Amersham Biosciences, Bukinghamshire, UK).
2.8. DNA mutation
Luciferase reporter pGL3 plasmid including 50-ﬂanking region
(from 1302 to +123 bp) of the human COX-2 gene was kindly
provided by Dr. S. Prescott (University of Utah, Salt Lake). DNA
fragments of various lengths of the COX-2 promoter were prepared
by PCR using the pGL3 plasmid as the template and subsequently
subcloned into pGL3 plasmid. The mutant CRE1, CRE2 and CRE1/
CRE2 plasmid clones were constructed by using Site-Directed
Mutagenesis Kit (Stratagene, CA, USA). Primers for mutagenesis is
as followings; CRE1, 50-cagcctattaagcgtcgtgactaaaacataaaac-30;
CRE2, 50-gaaacagtcatttcgtgacatgggcttgg-30. Underlined regions
indicate location of the speciﬁed response elements in the wild-
type sequence; mutated bases are in bold. The correct clones were
conﬁrmed by sequencing.
2.9. Luciferase assay
For luciferase assay, calvarial osteoblasts were transfected with
1.5 lg pGL3-COX-2 promoter- or pCRE-luciferase reporter plasmid
(Stratagene, CA, USA) and 0.5 lg pCMV-b-galactosidase plasmid.
Cells were then incubated with PTH (100 nM) or rolipram
(10 lM) for 6–8 h. Cells were harvested and lysed in a reporter ly-
sis buffer, and the cleared lysates were transferred to each tube,
and luciferase assay reagent (Promega, WI, USA) was added. The
light intensity of the reaction was determined using a luminometer
(Turner Biosystems Inc., Sunnyvale, CA) and the luciferase activity
was normalized to b-galactosidase activity.
2.10. Overexpression of DN-CREB (CRE-binding protein)
Dominant-negative (DN)-CREB (pCMV-KCREB, that contains
mutations in its DNA-binding domain) and wild-type (WT)-CREB
(pCMV-CREB) were purchased from Clontech (Palo Alto, CA).
Mouse osteoblastic MC-4 cells were co-transfected with pCRE-
Luc, pCMV-b-galactosidase plasmid and (DN)-CREB, and transfec-
ted cells were selected with G418 (Sigma–Aldrich, USA). Transfec-
ted cells were treated with PTH (100 nM) or rolipram (10 lM) for
indicated time, and then harvested with easy-BLUE for Northern
blot analysis or reporter lysis buffer for luciferase assay.
2.11. Statistical analysis
Data are presented as the means + S.D. from at least three inde-
pendent experiments.
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ance followed by the Student’s t-test. A P value <0.05 was consid-
ered statistically signiﬁcant.3. Results
3.1. PTH-induced cAMP production is negatively regulated by PDE4 in
osteoblasts
PTH increases the intracellular cAMP concentration by activat-
ing adenylate cyclase (AC) in osteoblasts. Although the repertoire
of PDEs expressed in osteoblasts was deﬁned using RT-PCR [14],
the PDE isozymes involved in the regulation of PTH-induced cAMP
production are unknown. Thus, we attempted to verify the PTH-
dependent PDE isozymes in osteoblasts by treating cells with
PTH for 1 h in the presence of inhibitors of PDE1, 2, 3, 4, and 8,
which degrade cAMP. Among the various cAMP-speciﬁc PDE inhib-
itors, only an inhibitor of PDE4 permitted an increase in PTH-in-
duced cAMP concentration (Fig. 1A), suggesting that PDE4
regulates PTH-induced cAMP production in osteoblasts.
To understand how PDE4 regulates PTH-induced cAMP produc-
tion, we examined cAMP levels in the presence of PTH and/or PDE4
inhibitor over time (Fig. 1B). PTH stimulated cAMP production
within 5 min; however, a return to the baseline value was observed
after 1 h. In contrast, treatment with PDE4 inhibitor plus PTH re-
sulted in relatively high sustained levels of cAMP for up to 3 h,
indicating that the degradation of PTH-induced cAMP was blocked
by PDE4 inhibitor.In
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Fig. 1. The regulation of PTH-induced cAMP accumulation by PDEs in osteoblasts. (A) Cal
presence of vinpocetine (30 lM), EHNA (10 lM), milrinone (10 lM), rolipram (10 lM), or
which the intracellular cAMP concentration was determined by EIA. *P < 0.05 versus PTH.
presence of 10 lM rolipram for the indicated time intervals. The intracellular cAMP conce
the means + S.D. of triplicate cultures.3.2. PDE4 inhibitor stimulates RANKL-induced osteoclast formation
PTH induces osteoclast formation via cAMP-mediated pathways
in osteoblasts [6]. Because PDE4 negatively regulates PTH-induced
cAMP, we explored the effects of PDE inhibitors on PTH-induced
osteoclast formation in co-cultures of mouse bone marrow cells
and calvarial osteoblasts (Fig. 2A and B). Consistent with the con-
centration of cAMP, PDE4 inhibitor dramatically increased osteo-
clast formation in the presence of PTH in a dose-dependent
manner. In contrast, inhibitors of PDE1, 2, 3, and 8 had no effect.
RANKL expression is known to inﬂuence osteoclastogenesis [3–
5]; thus, we next investigated whether PDE4 inhibitor affected
PTH-induced RANKL mRNA expression (Fig. 2C and D). Northern
blotting revealed that PDE4 inhibitor increased RANKL mRNA
expression in the presence of PTH in a dose-dependent manner,
with maximum expression at 3 h after treatment. Taken together,
these data indicate that PDE4 inhibitor promotes RANKL-induced
osteoclast formation via PTH-induced cAMP production in
osteoblasts.
3.3. PDE4 inhibitor-induced osteoclast formation is attributable to
CRE-mediated COX-2 expression
We previously suggested that PTH induces COX-2mRNA expres-
sion, which in turn promotes RANKL mRNA expression in osteo-
blasts [7]. In accordance with our previous results, we found that
PDE4 inhibitor potentiated the PTH-induced mRNA expression of
COX-2 in osteoblasts (Fig. 3A). These data suggest the possibility
that increased COX-2mRNA expression is attributable to the syner-*
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Fig. 2. The involvement of PDEs in PTH-induced osteoclast formation. (A) Mouse bone marrow cells and calvarial osteoblasts were co-cultured with vehicle or 100 nM PTH in
the presence of vinpocetine (30 lM), EHNA (10 lM), milrinone (10 lM), rolipram (10 lM), or dipyridamole (30 lM) (selective inhibitors of PDE1, 2, 3, 4, and 8, respectively).
(B) Mouse bone marrow cells and calvarial osteoblasts were co-cultured with vehicle or 100 nM PTH in the presence of various concentrations of rolipram for 6 days. The cells
were then ﬁxed and stained for TRAP and the number of TRAP-positive (+) multinucleated cells (MNCs) was determined. The data are expressed as the means + S.D. of
triplicate cultures. (C and D) Calvarial osteoblasts were treated with 100 nM PTH in the presence of the indicated concentrations of rolipram for 3 h (C) or in the presence of
10 lM rolipram for the indicated time intervals (D). RANKL mRNA expression was determined by Northern blotting. *P < 0.001 versus PTH ().
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tion. Thus, we investigated the role of COX-2 on osteoclast forma-
tion and RANKL mRNA expression by gene knock-down. We
conﬁrmed that protein levels of COX-2 were decreased in COX-2
speciﬁc siRNA-transfected osteoblasts compared with scrambled
siRNA-transfected cells (Fig. 3B). Furthermore, we found that intro-
duction of COX-2 siRNA in osteoblasts decreased the PDE4 inhibi-
tor-induced osteoclast formation (Fig. 3C) and RANKL mRNA level
(Fig. 3D) in the presence or absence of PTH. These data suggest that
COX-2 partially mediates the PDE4 inhibitor-enhanced effects of
PTH on osteoclast formation and RANKL mRNA expression.
Because the upregulation of COX-2 mRNA in response to PDE4
inhibitor is thought to enhance osteoclast formation, we explored
the transcriptional regulation of COX-2 using PDE4 inhibitor
(Fig. 4). We studied COX-2 promoter-driven transcription in osteo-
blasts transiently transfected with the reporter plasmid pGL3-basic
containing DNA spanning the transcription start site of human
COX-2 (1302 to +123 bp). As shown in Fig. 4A, luciferase activity
increased upon activation by PDE4 inhibitor. To map the regionsresponsible for this induction, 50-deletion constructs lacking the re-
gions indicated in Fig. 4A were generated. No induction of pro-
moter activity following stimulation with PDE4 inhibitor was
observed when using the reporter construct containing bases
522 to +123, indicating that a critical regulatory region between
742 and522 bp is responsible for this induction. Sequence anal-
ysis revealed the existence of two putative CRE-binding sites at
positions 567 and 56.
To determine the role of these sites in PDE4 inhibitor-induced
transcription of COX-2, site-directed mutagenesis was employed
to modulate the two CRE sites (567/56) located in the COX-2
promoter. As shown in Fig. 4B, cells transfected with constructs
containing the wild-type COX-2 promoter showed increased COX-
2 promoter activity in response to PDE4 inhibitor. However, the
mutation of one or both CRE sites signiﬁcantly reduced PDE4 inhib-
itor-induced COX-2 promoter activity, suggesting that these sites
play a major role in PDE4 inhibitor-induced COX-2 transcription.
We conﬁrmed the involvement of these sites using a CRE-luciferase
reporter construct (Fig. 4C). PDE4 inhibitor induced CRE-depen-
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Fig. 3. The involvement of COX-2 in the effect of PDE4 inhibitor. (A) Calvarial osteoblasts were treated with 100 nM PTH and/or 10 lM rolipram for 1 h, and COX-2 mRNA
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presence of PTH.
Transcription factors known to bind the CRE site in the human
COX-2 promoter include AP-1, ATF, and CREB. It has been reported
that CREB mediates RANKL expression in osteoblasts [6]; thus, we
directly assessed the involvement of CREB in PDE4 inhibitor-in-
duced COX-2 expression using loss-of-function analysis (Fig. 5).
First, we expressed wild-type (CREB) or a dominant-negative CREB
mutant (DN-CREB) in osteoblasts, and assessed CRE-dependentluciferase activity in the presence of PDE4 inhibitor. DN-CREB over-
expression completely abolished PDE4 inhibitor-induced CRE acti-
vation (Fig. 5A). Furthermore, DN-CREB overexpression reduced
the mRNA expression of COX-2 in PDE4 inhibitor-stimulated oste-
oblasts (Fig. 5B), suggesting that the binding of CREB to CRE sites is
essential for PDE4 inhibitor-induced COX-2 expression. Similarly,
PTH failed to induce COX-2 mRNA expression or CRE-dependent
luciferase activity in the presence of DN-CREB (Fig. 5A and B). Ta-
ken together, these data indicate that PDE4 inhibitor promotes
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2 mRNA expression in osteoblasts.
4. Discussion
PTH binds to osteoblast lineage cells, producing both anabolic
and catabolic effects depending on the method of administration
[15]. The intermittent administration of PTH has net anabolic ef-fects on bone, and the mechanism by which PTH augments bone
formation has been examined in detail. The anabolic effect of
PTH is largely due to a rise in osteoblast number as a result of
the increased proliferation and differentiation of osteoblasts
in vitro and in vivo, a decrease in osteoblast apoptosis, and the acti-
vation of bone-lining cells [15]. On the other hand, the continuous
administration of PTH induces bone resorption by stimulating
osteoclast formation indirectly through the upregulated expression
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Fig. 5. Involvement of CRE sites in COX-2 mRNA expression induced by PDE4
inhibitor. (A and B) MC-4 osteoblastic cells were transfected with wild-type CREB or
DN-CREB, and then treated with PTH (100 nM) or rolipram (10 lM) for 8 h (A) or 1 h
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COX-2 mRNA expression was measured by Northern blotting (B). *P < 0.005 versus
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mediates PTH-induced RANKL expression, the mechanism underly-
ing the catabolic effect of PTH is less well understood.
PTH-induced cAMP accumulation is typically transient because
numerous feedback systems are activated that ﬁnely tune the
cAMP signal in terms of intensity, time, and its propagation
through the intracellular space. The mechanisms underlying this
transient response have been studied extensively and are thought
to include the rapid phosphorylation of PTHR1 by GPCR kinase
(GRK), as well as the binding of adaptor molecules such as b-arres-
tins, which promote the uncoupling and desensitization of the
receptor [17]. Indeed, GRK inhibition increased RANKL mRNA
expression in vivo, resulting in enhanced osteoclastic activity [18].
Here, we found that PDE4 is an important component responsi-
ble for shaping and controlling the transient nature of the cAMP
signal produced in response to PTH stimulation. Our data show
that the duration of cAMP activation in response to PTH is sus-
tained by the selective PDE4 inhibitor rolipram (Fig. 1B); however,
the involvement of other PDE families cannot be excluded. Our re-
sults also suggest a mechanism of action wherein PDE4 inhibition
promotes PTH-induced osteoclast formation. A previous examina-
tion of the molecular mechanism of PTH-induced RANKL expres-
sion in osteoblasts revealed the involvement of COX-2 [7].
Indeed, PDE4 inhibition enhanced PTH-induced COX-2 mRNA
expression, which partially mediates increased RANKL mRNA
expression and osteoclast formation (Fig. 3).
We also showed that PTH-stimulated RANKL mRNA expression
and osteoclast formation are mediated partially by COX-2. PTH is
able to directly stimulate cAMP production in addition to indirectly
stimulating cAMP via COX-2. The direct effect of PTH is thought to
be immediate and transient, whereas the indirect effect of PTH
may take longer time. Since we investigated later responses by
PTH in this study, the COX-2 dependent effects of PTH may not re-
ﬂect the direct effects of PTH.We attempted to identify the transcriptional response elements
in the COX-2 promoter region that contribute to the induction of
COX-2 mRNA expression in response to PDE4 inhibition. Deletion
and mutation analyses indicated that the PDE4 inhibitor-induced
upregulation of COX-2 is mediated by the CRE region of the human
COX-2 promoter (Fig. 4). The involvement of these sites in PDE4
inhibitor-induced COX-2 mRNA expression was also conﬁrmed by
the co-expression of a dominant-negative CREB mutant (DN-
CREB). The downregulation of CREB activity blocked COX-2 mRNA
expression as well as the CRE-dependent luciferase response to
PDE4 inhibitor (Fig. 5). These results indicate that CREB is required
for the induction of COX-2 mRNA expression following PDE4
inhibition.
PDE4 inhibitors have been extensively studied as anti-inﬂam-
matory compounds for the treatment of asthma and COPD, as well
as for rheumatoid arthritis, multiple sclerosis, type 2 diabetes, sep-
tic shock, leukemia, atopic dermatitis, and other autoimmune dis-
eases [19]. More recently, there has been a rekindling of interest in
the use of PDE4 inhibitors for the treatment of osteoporosis.
Although PTH was recently approved for and is widely used in ana-
bolic bone therapy, the cost, efﬁcacy, and risk of side effects asso-
ciated with this compound limit its use in the treatment of
osteoporosis [20]. Our results indicate that PDE4 negatively regu-
lates PTH in osteoblasts; thus, the simultaneous administration
of PDE4 inhibitor and PTHmay have synergistic effects in the treat-
ment of osteoporosis.
In conclusion, our study demonstrates that PDE4 inhibitor en-
hances PTH-induced osteoclast formation, which is partially attrib-
utable to CRE-mediated COX-2 expression.Acknowledgments
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